Jens Kemp - 26 Feb 2026 Form 4 Insider Report for Axogen, Inc. (AXGN)

Reporting relationship: Chief Marketing Officer
Issuer ticker: AXGN
Reported as of: 26 Feb 2026
Net transaction value: -$582,185
SEC form: 4
Accepted by SEC: 02 Mar 2026, 18:16:56 UTC
Prior SEC filing: 10 Dec 2025
Next SEC filing: 08 May 2026
Source filing: View source filing
Reporting owner signature: Marc Began, as attorney-in-fact for Jens Kemp

Key filing fact

Jens Kemp filed Form 4 for Axogen, Inc. (AXGN) on 02 Mar 2026.

Key facts

This page summarizes Jens Kemp's Form 4 filing for Axogen, Inc. (AXGN).
4 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 02 Mar 2026, 18:16.

Change

Previous filing in this sequence was filed on 10 Dec 2025.
Current net transaction value: -$582,185.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002007485 Primary reporting owner

Kemp Jens

Relationship: Chief Marketing Officer
Address: 13631 PROGRESS BLVD.,, SUITE 400, ALACHUA
Signature: Marc Began, as attorney-in-fact for Jens Kemp
Signature date: 02 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AXGN transaction

Common Stock

Award

Transaction value: $0
Shares: +50,670
Change %: +115%
Price: $0.000000
Shares after: 94,817
Date: 26 Feb 2026
Ownership: Direct
Footnotes: F1, F2, F3

AXGN transaction

Common Stock

Tax liability

Transaction value: $491,707
Shares: -15,414
Change %: -16%
Price: $31.90
Shares after: 79,403
Date: 26 Feb 2026
Ownership: Direct
Footnotes: F4

AXGN transaction

Common Stock

Tax liability

Transaction value: $90,479
Shares: -2,952
Change %: -3.7%
Price: $30.65
Shares after: 76,451
Date: 01 Mar 2026
Ownership: Direct
Footnotes: F5

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AXGN transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +23,000
Change %
Price: $0.000000
Shares after: 23,000
Date: 26 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 23,000
Exercise price
Footnotes: F6, F7

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 7 footnotes

Footnote F1

This reflects the number of shares that became vested as of February 26, 2026, upon the attainment and certification of certain performance criteria.

Footnote F2

The previous Form 4 filed by the Reporting Person overstated the number of shares beneficially owned by the Reporting Person by 4,003 shares of Common Stock. The amount reported herein has been corrected.

Footnote F3

Includes 2,120 shares acquired under the Axogen Employee Stock Purchase Plan on December 31, 2025.

Footnote F4

No shares were sold by the reporting person. The transaction disclosed represents shares of the issuer's Common Stock withheld by the issuer in payment of the withholding tax liability incurred upon the vesting of performance stock units ("PSUs").

Footnote F5

Footnote F6

Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

Footnote F7

All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on February 26, 2030 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on February 26, 2028 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.